An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
LENSAR, Inc. (NASDAQ: LNSR) will release its second quarter 2022 financial results on August 8, 2022, before market open. A conference call and webcast will follow at 8:30 am ET on the same day, where management will discuss the financial results and corporate highlights. The company specializes in advanced femtosecond laser surgical solutions for cataracts, notably with its ALLY™ Adaptive Cataract Treatment System, which enhances operational efficiency and surgical outcomes.
Positive
Preparation to release financial results may indicate transparency and commitment to communicating with investors.
Advanced technologies in cataract surgery with the ALLY™ system could lead to improved market positioning.
Negative
The company's upcoming financial results may reveal potential declines in revenue or other metrics.
ORLANDO, Fla.--(BUSINESS WIRE)--
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s second quarter 2022 financial results will be released before market open on Monday, August 8, 2022. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Monday, August 8, 2022 to discuss the financial results and recent corporate highlights.
To participate by telephone, please dial (888) 396-8049 (Domestic) or (416) 764-8646 (International). The conference ID number is 64265948. To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com. Following the live webcast, an archived version of the call will be available on the website.
About LENSAR LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of visually significant astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY™ Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging with a dual-pulse femtosecond laser in a compact system. ALLY is designed to transform cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
